Society of Interventional Radiology Features Radiofrequency Ablation in Press Release
31 Marzo 2006 - 8:38PM
PR Newswire (US)
SIR Press Release Highlights Three-Year Clinical Data Showing
Radiofrequency Ablation Treatment Effective as Surgical Resection
in Select Primary Liver Cancer Patients FREMONT, Calif., March 31
/PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (NASDAQ:RITA),
a publicly-traded medical device company focused solely on cancer
therapies, today announced the distribution of a press release by
the Society of Interventional Radiology (SIR) entitled, "Minimally
Invasive Radiofrequency Ablation Equally Effective As Surgical
Resection for Small Liver Tumors." The press release highlights
clinical study results presented by Dr. Riccardo Lencioni,
Professor of Radiology at the University of Pisa, Italy. Dr.
Lencioni presented his results at the SIR 31st Annual Scientific
Meeting in Toronto, Ontario, Canada. In the matched, case-control
study of 162 patients treated with surgical resection or
radiofrequency ablation (RFA), researchers reported overall
survival rates were 72% at 3 years in the RFA group, versus 65% at
3 years in the surgical resection group. The scientific abstract of
the presentation is available on the SIR Annual Meeting website, at
http://www.sirmeeting.org/. Click on "Program," then "Scientific
Presentations," and then "Abstract Presentations," and search for
abstract number 1021. The same link may be used to do a subject
search for other presentations on the topic of radiofrequency
ablation. Dr. Jelle Kylstra, Vice President and Medical Director of
RITA Medical Systems commented, "According to the case-control
study, for this group of patients with solitary primary liver
tumors, radiofrequency ablation provides survival comparable to the
traditional "gold standard" treatment of surgical resection. We
believe that patients realize this benefit without the
complications and morbidity often associated with surgery, and
typically return home within 24 hours after the procedure." About
RITA Medical Systems, Inc. RITA Medical Systems develops,
manufactures and markets innovative products for cancer patients
including radiofrequency ablation (RFA) systems for treating
cancerous tumors as well as percutaneous vascular and spinal access
systems. The Company's oncology product lines include implantable
ports, some of which feature its proprietary Vortex(R) technology;
tunneled central venous catheters; and safety infusion sets and
peripherally inserted central catheters used primarily in cancer
treatment protocols. The product line also includes the HABIB 4X
resection device which coagulates a surgical resection plane and is
designed to facilitate a fast dissection in order to minimize blood
loss and blood transfusion during surgery. The proprietary RITA RFA
system uses radiofrequency energy to heat tissue to a high enough
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA Company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
again became the first company to receive specific FDA clearance,
this time for the palliation of pain associated with metastatic
lesions involving bone. The RITA Medical Systems website is at
http://www.ritamedical.com/. The statements in this news release
related to the efficacy, benefits and safety of RFA technology,
including without limitation physician adoption of RFA treatment
for liver cancer, are forward-looking statements involving risks
and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements. Such
risks and uncertainties include but are not limited to: the
Company's ability to compete with companies with greater resources;
the existence of alternative therapies that could prove to be
superior to RFA; the lack of long-term data regarding the safety
and efficacy of its RFA products; delay of product introductions or
modifications as a result of the FDA regulatory process; and the
Company's success in its physician training efforts. Information
regarding these risks and other risks and uncertainties is included
in the Company's filings with the Securities and Exchange
Commission. DATASOURCE: RITA Medical Systems, Inc. CONTACT: media,
Steve DiMattia, +1-646-277-8706, or , or investors, Doug Sherk, ,
or Jennifer Beugelmans, both at +1-415-896-6820, all of EVC Group
for RITA Medical Systems, Inc.; or Stephen Pedroff, VP Marketing
Communications of RITA Medical Systems, Inc., +1-510-771-0400, or
Web site: http://www.ritamedical.com/
Copyright
Grafico Azioni Rita Medical (NASDAQ:RITA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Rita Medical (NASDAQ:RITA)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Rita Medical Systems (NASDAQ): 0 articoli recenti
Più Rita Medical Systems (MM) Articoli Notizie